A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US (NCT06952426)
A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
🩺 Plain-English Summary (8th-Grade Level)
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (0 items).
Location: Novartis Investigational site — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
- No intervention (OTHER)
- Other treatment (OTHER)
- Iptacopan (OTHER)
- Atrasentan (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Novartis Investigational site — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: +41613241111
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Immunoglobulin A Nephropathy
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) — Birmingham, Alabama
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Alabaster, Alabama
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Huntsville, Alabama
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy — Birmingham, Alabama
Explore by condition: All Immunoglobulin A Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.